Trial results

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

NCT00354536 on ClinicalTrials.gov · last registry update 2016-10-26

Finished September 2006, after enrolling 60 people. Primary outcome, as filed: blood plasma levels of GSK716155. albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P2

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

60

Started

2006-02

Primary completion

2006-09 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

blood plasma levels of GSK716155

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.